跳至主要内容
临床试验/NCT00532571
NCT00532571已完成2 期

Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

Lahey Clinic2 个研究点 分布在 1 个国家开始时间: 2004年1月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Lahey Clinic
试验地点
2

研究概览

简要总结

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
  • Age > 40
  • Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
  • Patients agreeable to participate in the study.

排除标准

  • Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
  • Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
  • History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Previous use of coenzyme Q10 within 60 days of the baseline visit.

研究者

发起方
Lahey Clinic
申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Effects of Coenzyme Q10 in PSP and CBD | 临床试验